The industry urgently needs to understand that its current approach to policy is almost pre-destined to deliver disappointment and poor outcomes.
The choice is to be more defensive or continue to suffer bad outcomes
September 19, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Pfizer commissioned polling finds strong public support for investing in the PBS
November 9, 2026 - - Latest News -
Pfizer confirms Ben Fitzsimmons as Australia and New Zealand chief
November 9, 2026 - - Latest News -
Coalition edges ahead in New Zealand as Stephenson returns and Pharmac pledges await the 'specials'
November 9, 2026 - - Latest News -
Celairis launches with plan to end the region's place at the rear of the launch queue
November 9, 2026 -

